Journal of Shanghai Jiao Tong University (Medical Science) >

2024 , Vol. 44 >Issue 1: 23 - 34

DOI: https://doi.org/10.3969/j.issn.1674-8115.2024.01.003

Basic research

Expression of adhesion G protein-coupled receptor F1 in pancreatic ductal adenocarcinoma and its mechanism of promoting cancer progression

  • Suyuan CHEN ,
  • Musitaba Mutailifu ,
  • Dongxue LI ,
  • Zhigang ZHANG
Expand
  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200240, China
LI Dongxue, E-mail: dxli@shsci.org.
ZHANG Zhigang, E-mail: zzhang@shsci.org

Received date: 2023-05-31

  Accepted date: 2023-09-18

  Online published: 2024-01-28

Supported by

National Natural Science Foundation of China(82203228);Science and Technology Innovation Action Plan of Shanghai Municipal Science and Technology Commission(22YF1445600);Medicine and Engineering Interdisciplinary Research Fund of Shanghai Jiao Tong University(YG2021ZD08);"Two-hundred Talents" Program of Shanghai Jiao Tong University School of Medicine(20181708)

Fold

Abstract

Objective ·To analyze the expression changes of adhesion G protein-coupled receptor F1 (ADGRF1) in the occurrence and development of pancreatic ductal adenocarcinoma (PDAC), and explore the impact of ADGRF1 on the proliferation of PDAC cells and the potential molecular mechanisms that promote PDAC progression. Methods ·The expression of ADGRF1 at mRNA level was analyzed based on the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) database, respectively. The expression of ADGRF1 in normal pancreatic ductal epithelial cells (hTERT-HPNE) and various PDAC tumor cells was detected by using real-time fluorescence quantitative PCR (qPCR) and Western blotting. Immunohistochemical staining (IHC) was used to detect the differential expression of ADGRF1 in cancer tissues and adjacent tissues of PDAC patients. After knocking down ADGRF1 with small interfering RNA (siRNA) transfection, the changes in the proliferation ability of PDAC AsPC-1 and SW1990 cells were detected through CCK8 assay and plate cloning experiment. Stable overexpression of ADGRF1 was constructed in PDAC Patu8988 cell line, and the proliferation changes induced by overexpression of ADGRF1 were evaluated through CCK8 assay. RNA sequencing (RNA-seq), gene set enrichment analysis (GSEA), and immune infiltration analysis were utilized to predict signaling pathways associated with ADGRF1-mediated promotion of PDAC cancer progression. Results ·Analysis of the TCGA database and GEO database revealed higher expression of ADGRF1 mRNA in PDAC tissues compared to normal pancreatic tissues (all P=0.000). qPCR and Western blotting results demonstrated up-regulation of ADGRF1 mRNA and protein levels in various PDAC cells compared to hTERT-HPNE cells (all P<0.05). IHC results confirmed higher ADGRF1 expression in PDAC cancer tissues compared to adjacent tissues. Furthermore, downregulation of ADGRF1 inhibited the proliferation of PDAC AsPC-1 and SW1990 cell lines, while overexpression of ADGRF1 promoted the proliferation of Patu8988 cells (all P<0.05). RNA-seq, GSEA enrichment analysis, and immune infiltration analysis revealed that ADGRF1 expression was related to signaling pathways such as interferon-α (IFN-α), tumor necrosis factor-α (TNF-α), and nuclear factor κB (NF-κB). Conclusion ·ADGRF1 is highly expressed in PDAC cells and tissues, and promotes the proliferation of PDAC cells via immune-related signaling pathways.

Key words： pancreatic ductal adenocarcinoma (PDAC); adhesion G protein-coupled receptor F1 (ADGRF1); immunity; tumor-promoting effect

Cite this article

Suyuan CHEN , Musitaba Mutailifu , Dongxue LI , Zhigang ZHANG . Expression of adhesion G protein-coupled receptor F1 in pancreatic ductal adenocarcinoma and its mechanism of promoting cancer progression[J]. Journal of Shanghai Jiao Tong University (Medical Science), 2024 , 44(1) : 23 -34 . DOI: 10.3969/j.issn.1674-8115.2024.01.003

References

1 BENGTSSON A, ANDERSSON R, ANSARI D. The actual 5-year survivors of pancreatic ductal adenocarcinoma based on real-world data[J]. Sci Rep, 2020, 10(1): 16425.
2 GUO X F, SONG Y N, XU P J, et al. Selective extended dissection for pancreaticoduodenectomy is associated with better survival in pancreatic cancer patients: retrospective cohort study[J]. Int J Surg, 2023, 109(7): 1852-1862.
3 GOTTUMUKKALA S, SALAMEKH S, SANFORD N N. Current state and future directions of radiation therapy for pancreas adenocarcinoma[J]. Surg Oncol Clin N Am, 2023, 32(3): 399-414.
4 SMAGLO B G. Role for neoadjuvant systemic therapy for potentially resectable pancreatic cancer[J]. Cancers, 2023, 15(8): 2377.
5 REGAN S L, WILLIAMS M T, VORHEES C V. Latrophilin-3 disruption: effects on brain and behavior[J]. Neurosci Biobehav Rev, 2021, 127: 619-629.
6 HAMANN J, AUST G, ARA? D, et al. International Union of Basic and Clinical Pharmacology. ⅩCⅣ. Adhesion G protein-coupled receptors[J]. Pharmacol Rev, 2015, 67(2): 338-367.
7 LIEBSCHER I, CEVHERO?LU O, HSIAO C C, et al. A guide to adhesion GPCR research[J]. FEBS J, 2022, 289(24): 7610-7630.
8 SASAKI S I, ZHANG D, IWABUCHI S, et al. Crucial contribution of GPR56/ADGRG1, expressed by breast cancer cells, to bone metastasis formation[J]. Cancer Sci, 2021, 112(12): 4883-4893.
9 WU G X, ZHAI D F, XIE J M, et al. N6-methyladenosine (m6 A) RNA modification of G protein-coupled receptor 133 increases proliferation of lung adenocarcinoma[J]. FEBS Open Bio, 2022, 12(3): 571-581.
10 MOSCA S, CARDINALI G, FLORI E, et al. The PI3K pathway induced by αMSH exerts a negative feedback on melanogenesis and contributes to the release of pigment[J]. Pigment Cell Melanoma Res, 2021, 34(1): 72-88.
11 ABBAS A, JUN P, YUAN J Y, et al. Downregulation of GPR160 inhibits the progression of glioma through suppressing epithelial to mesenchymal transition (EMT) biomarkers[J]. Basic Clin Pharmacol Toxicol, 2022, 131(4): 241-250.
12 LUM A M, WANG B B, BECK-ENGESER G B, et al. Orphan receptor GPR110, an oncogene overexpressed in lung and prostate cancer[J]. BMC Cancer, 2010, 10: 40.
13 MA B T, ZHU J J, TAN J, et al. Gpr110 deficiency decelerates carcinogen-induced hepatocarcinogenesis via activation of the IL-6/STAT3 pathway[J]. Am J Cancer Res, 2017, 7(3): 433-447.
14 BHAT R R, YADAV P, SAHAY D, et al. GPCRs profiling and identification of GPR110 as a potential new target in HER2+ breast cancer[J]. Breast Cancer Res Treat, 2018, 170(2): 279-292.
15 ZHU X L, HUANG G Q, JIN P F. Clinicopathological and prognostic significance of aberrant G protein-couple receptor 110 (GPR110) expression in gastric cancer[J]. Pathol Res Pract, 2019, 215(3): 539-545.
16 DE GROOT D M, VOGEL G, DULOS J, et al. Therapeutic antibody targeting of CD97 in experimental arthritis: the role of antigen expression, shedding, and internalization on the pharmacokinetics of anti-CD97 monoclonal antibody 1B2[J]. J Immunol, 2009, 183(6): 4127-4134.
17 GIERA S, LUO R, YING Y Q, et al. Microglial transglutaminase-2 drives myelination and myelin repair via GPR56/ADGRG1 in oligodendrocyte precursor cells[J]. eLife, 2018, 7: e33385.
18 NILE A H, HANNOUSH R N. Fatty acid recognition in the Frizzled receptor family[J]. J Biol Chem, 2019, 294(2): 726-736.
19 LIU Z Q, ZHANG G R, ZHAO C L, et al. Clinical significance of G protein-coupled receptor 110 (GPR110) as a novel prognostic biomarker in osteosarcoma[J]. Med Sci Monit, 2018, 24: 5216-5224.
20 ABDULKAREEM N M, BHAT R, QIN L F, et al. A novel role of ADGRF1 (GPR110) in promoting cellular quiescence and chemoresistance in human epidermal growth factor receptor 2-positive breast cancer[J]. FASEB J, 2021, 35(7): e21719.
Options
Outlines

/

〈 〉